Search clinical trials for: Arbaclofen Placarbil IR

Total 485 results

RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS (OS440-3005)

Multiple Sclerosis | Spasticity, Muscle

United States
Incyte Corporation

Completed

A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.

Healthy Participants

United States
LGD
ProRelix Services LLP

Active, not recruiting

Safety and Efficacy of Orally Administered NUV001 Nutraceutical Supplement in Sickle Cell Disease Patients

Sickle Cell Disease

India
Janssen Research & Development, LLC

Completed

Effect of Food on a Fixed Dose Combination Tablet of Canagliflozin and Metformin Immediate Release in Healthy Volunteers

Healthy
MapLight Therapeutics

Enrolling by invitation

ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)

Autism Spectrum Disorder

United States, Canada, Australia
Tanta University

Unknown

Baclofen in the Treatment of Muscle Cramps in Patients With Cirrhosis

Liver Cirrhosis | Muscle Cramps

Egypt
Daewoong Pharmaceutical Co. LTD.

Completed

Study to Evaluate Drug-Drug Interaction of DWP16001 in Combination With Metformin in Healthy Male Adults (Phase 1 Study)

Healthy

Korea, Republic of
Bristol-Myers Squibb

Completed

Assessment of Blood Glucose Changes in Healthy Volunteers After BMS-754807 Alone or BMS-754807 With Metformin (NHV)

Healthy Volunteers

Australia
Bellus Health Inc. - a GSK company

Recruiting

Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference Formulation

Healthy | Cough

United Kingdom
Memorial Sloan Kettering Cancer Center

Completed

Image-Guided Navigation for High Dose Rate Temporary Interstitial Brachytherapy in the Palliative Management of Previously Treated Tumors of the Spine and Pelvis

Metastatic or Recurrent Lesions in the Spine | Metastatic or Recurrent Lesions in the Pelvis

United States
Ward Photonics LLC

Withdrawn

Effects of a Red/Gold/IR LED Combination Light on Reduction of Fat

Diabetes Mellitus, Type 2 | Body Image

United States
Abbott Medical Optics

Completed

Prospective S&E Study of Wavefront-guided PRK for Myopia With iDesign Advanced Wavescan Studio™ System and Star S4 IR™

Stable Myopic Refractive Error, With or Without Astigmatism

United States
GlaxoSmithKline

Completed

Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib

Cancer

Australia
Merck KGaA, Darmstadt, Germany

Completed

Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes (CONSENT)

Diabetes Mellitus, Type 2

Germany
Anji Pharma

Completed

A Phase 1 Study of ANJ900 Chinese Healthy Subjects

Healthy

China
Yale University
CIRCUFIBER, Inc.

Completed

Infrared Wraps Effect on Oxygenation of Diabetics Arm, Feet and Lower Leg

Diabetes

United States
Zurich University of Applied Sciences

Completed

Sport Specific Adaptions in Female Volleyball Players

Overuse Related Shoulder Problems

Switzerland
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg/850 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin IR Tablets (2 x 850 mg) in Healthy Volunteers

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers

Healthy

United States
Eli Sprecher, MD

Recruiting

The Assessment of Infrared Treatment for Crohn's Disease

Inflammatory Bowel Diseases | Crohn Disease | IBD

Israel
Assiut University

Not yet recruiting

Association Between Triglycerides Glucose Ratio With HOMA -IR as Indicators of Insulin Resistance in Obese Adults

Insulin Resistance
MapLight Therapeutics

Recruiting

ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)

Autism Spectrum Disorder

United States, Australia, Canada
GlaxoSmithKline

Completed

Insulin Resistance as Primary Pathogenesis in Newly Diagnosed, Drug naïve Type 2 Diabetes Patients in Korea (SURPRISE)

Diabetes Mellitus, Type 2

Korea, Republic of
Pfizer

Completed

Study of Controlled Release Formulations of CE-224,535 Against the Immediate Release Formulation in Normal Volunteers

Rheumatoid Arthritis

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Volunteers

Healthy

United States
Bristol-Myers Squibb

Completed

A Study to Assess the Bioavailability and Effect of Food of BMS-986419 Immediate-release Tablet Formulation in Healthy Adult Participants

Healthy Volunteers

United States
Galapagos NV

Completed

A Study Investigating the Safety, Absorption and Elimination of GLPG3312, a New Drug in the Treatment of Inflammatory Diseases

Healthy

Netherlands
Medical University of Graz
European Commission

Completed

Feasibility Study to Determine the Optimal Calibration Method for Glucose Sensors (REACT4SENSOR)

Diabetes

Austria
October 6 University

Completed

Effect of Shock Wave Therapy on Upper Trapezius Trigger Points in Patients With Cervicogenic Headache.

Cervicogenic Headache

Egypt
Eisai Co., Ltd.

Completed

A Pharmacokinetic (PK) Study of Three Types of E0302 Sustained Release (SR) Tablets Compared With E0302 Immediate Release (IR) Tablet Under Fed Conditions in Healthy Participants

Healthy Subjects

New Zealand
Stallergenes Greer

Completed

Phase III Study to Assess the Long Term Efficacy, Carry-over Effect and Safety of 300 IR Sublingual Immunotherapy Tablets

Allergy

France
Azurity Pharmaceuticals

Completed

Evaluation of Abuse Potential of HORIZANT Taken Alone and With Oxycodone in Healthy, Nondependent Recreational Opioid Users

Abuse Potential

United States
Anji Pharma

Suspended

Investigational Study of Delayed Release Metformin (DREAM-T2D)

Diabetes Mellitus, Type 2

Spain, United States, Canada, Hungary, Brazil, Czechia, Poland, Bulgaria
Impax Laboratories, LLC

Completed

Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease

Parkinson's Disease

United States
Stallergenes Greer

Completed

Safety and Efficacy of Sublingual Immunotherapy (SLIT) Tablets in Grass Pollen Rhinoconjunctivitis

Allergy
Stallergenes Greer

Completed

Safety and Efficacy on Phase III Study on 300 IR SLIT to Patients Suffering From Grass Pollen Rhinoconjunctivitis

Primary Disease

France, Italy, Spain
Stallergenes Greer

Completed

Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis

Allergic Rhinitis Due to Grass Pollens

United States
Medical University of Lodz

Completed

Comparison of Effectiveness and Safety of Sublingual Immunotherapy in Children With Allergic Rhinitis

Allergic Rhinitis

Poland
Geestelijke Gezondheidszorg Eindhoven (GGzE)
Maastricht University

Not yet recruiting

EMDR Versus Imagery Rescripting for Trauma-Related Intrusions

Depression | Stress Disorders, Post-Traumatic
Bayer

Completed

A Study to Learn How the Study Treatment BAY3283142 Taken as Single Dose by Mouth Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function of Similar Age, Gender, and Weight

Renal Impairment | Chronic Kidney Disease | Healthy Volunteers

Germany
Gui Xiaoting

Recruiting

Changes in Serum, Follicular Fluid SREBP1c and LRG1 Levels in PCOS Patients and Correlation With Insulin Resistance

PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries

China
NeuroDerm Ltd.

Active, not recruiting

Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)

Parkinson's Disease

United States, Israel, Spain, France, Russian Federation, Austria, Italy, Belgium, Czechia, Hungary, Netherlands, Poland, Portugal, Slovakia, Ukraine, United Kingdom
Pfizer
Medivation, Inc.

Completed

A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin

Alzheimer's Disease | Huntington's Disease

United States
Grünenthal GmbH

Completed

A Clinical Study in Healthy Women Which Aims to Explore the Intestinal Uptake of Two Different Tablets of GRTA9906 Into the Body and the Effect of Food on it

Pain | Chronic Pain | Neuropathic Pain | Visceral Pain

Germany
Stallergenes Greer

Active, not recruiting

Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Asthma (YOBI)

Allergic Rhinoconjunctivitis | Birch Pollen Allergy

Germany
Daewon Pharmaceutical Co., Ltd.

Completed

Phase 1 Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR and Pelubiprofen SR (as a Pelubiprofen 45 mg) Tablet in Healthy Subjects

Healthy Males
AMO Development, LLC

Recruiting

Wavefront-guided LASIK for Monovision Treatment of Myopic Subjects With Presbyopia

Refractive Error

United States
Elcelyx Therapeutics, Inc.

Completed

Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM

Type 2 Diabetes Mellitus

United States, Puerto Rico
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study of Multiple Doses of ORM-12741 (Nebula PK 2)

Healthy

Finland
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study of Single Doses of ORM-12741 (Nebula PK 1)

Healthy

Finland

3

Subscribe